DBVT News and Press, DBV Technologies S.A. From 04/21/22

Montrouge, France, April 21, 2022 Ordinary and Extraordinary General Meeting of May 12 , 2022 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DB...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Shares of DBV Technologies S.A. (NASDAQ:DBVT) traded at a new 52-week high today of $50.24. So far today approximately 39.1 million shares have been exchanged, as compared to an average 30-day volume of 154,000 shares. DBV Technologies S.A. has overhead space with shares priced $1.45, or...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Hycroft Mining (NASDAQ:HYMC) +84% AMC Entertainment is buying 22% of Hycroft Mining Holding. Incannex Healthcare (NASDAQ:IXHL) +66%. Excellon Resources (NYSE:EXN) +23%. Hollysys Automation Technologies (NASDAQ:HOLI) +12%. Anavex Life Sciences (NASDAQ:AVXL) +9% posts mid-st...

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Montrouge, France, March 9, 2022 DBV Technologies Announces Filing of 202 1 Annual Report on Form 10-K and 202 1 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage ...

Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%.  ...

Clinical-stage biotech, Humanigen (NASDAQ:HGEN) has added ~6% in the pre-market after two of the senior officers of the company, including Chief Executive Cameron Durrant, disclosed insider purchases through SEC filings on Friday. On Mar. 02, Cameron has bought 40,000 company s...